West Pharmaceutical Services, Inc. (WST) Balance Sheet

The sequential increase in assets, driven largely by a surge in PPE net to $3.4B from $1.5B over the period, indicates significant investment in capacity to meet biologics and GLP-1 demand. Equity growth outpaced asset growth, with retained earnings rising from $3.6B to $4.6B, suggesting strong earnings retention and a strengthening financial foundation. This trajectory implies the company is reinvesting for growth while maintaining a fortress-like balance sheet.

The low D/E ratio, combined with a debt-to-assets ratio of approximately 7.6%, suggests that debt is not a primary funding source but rather a strategic tool for operational flexibility. The stability of debt levels over the past ten quarters, despite significant capex, implies that internal cash generation is funding expansion, reducing refinancing risk. This conservative approach may limit financial risk but could also signal under-leveraging, potentially leaving value on the table.

The doubling of PPE over the period underscores a deliberate strategy to expand manufacturing capacity, likely for high-value products and GLP-1 components. The minimal goodwill (2.7% of total assets) suggests that growth is organic rather than acquisition-driven, reducing impairment risk. The asset mix now heavily favors productive capacity, which should support margin expansion if utilization rates remain high.

The growth in equity is almost entirely attributable to retained earnings, which increased by $1.0B over the period, while share counts remained stable. This indicates high earnings quality, as the company is not relying on external equity issuance or aggressive stock-based compensation to fund operations. The low SBC expense, as noted in the income statement analysis, further supports the integrity of the equity base.

The current ratio, consistently above 2.5, indicates a strong liquidity position, even after a drawdown in cash from $791.3M in 2025Q4 to $435.8M in 2026Q2, likely due to capex and buybacks. The cash balance still covers over 1.4x total debt, suggesting no near-term liquidity stress. This buffer provides flexibility to navigate the expected contract manufacturing wind-down in mid-2026 without compromising operations.